- Report
- November 2024
Japan, United States, ... Japan, United States, Europe, Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- October 2024
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- April 2022
Japan, United States, ... Japan, United States, Europe, Global
From €2625EUR$2,750USD£2,199GBP
- Report
- December 2021
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- August 2024
Japan, United States, ... Japan, United States, Europe
From €3340EUR$3,500USD£2,799GBP
The Aeromonads Test market is a subset of the Infectious Disease Testing market. It is focused on the detection of Aeromonas species, a group of Gram-negative bacteria that can cause a range of diseases in humans. Aeromonads Tests are used to diagnose infections, monitor treatment, and detect the presence of antibiotic-resistant strains. Tests are available in a variety of formats, including culture, PCR, and ELISA.
The Aeromonads Test market is driven by the increasing prevalence of Aeromonas infections, as well as the need for rapid and accurate diagnosis. The market is expected to grow in the coming years, as new technologies and improved diagnostics become available.
Some companies in the Aeromonads Test market include Bio-Rad Laboratories, Thermo Fisher Scientific, Becton Dickinson, and Roche Diagnostics. Show Less Read more